Patents Assigned to RX/IBR Corporation
  • Patent number: 6743411
    Abstract: A composition of matter comprises a pathogen-targeting organic moiety which is conjugated to a radioisotope which has a half-life of less than 100 days. The composition can be synthesized by bringing together a radioisotope having a half life of less than 100 days with a greater than stoichiometric amount of a complexing agent so as to form a first mixture containing a reaction product between the radioisotope and the complexing agent; removing the excess complexing agent from the mixture; and bringing together the first reaction product and an antibody substance so as to form a second mixture containing a reaction product between the first reaction product and the antibody substance. The composition is deposited on a particulate substrate and is useful for treating infectious diseases caused by pathogens by passing the patients blood through a bed formed from the particles.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: June 1, 2004
    Assignee: RX/IBR Corporation
    Inventor: Arthur Dale Ericsson
  • Patent number: 6706252
    Abstract: A composition of matter comprises a pathogen-targeting organic moiety which is conjugated to a radioisotope which has a half-life of less than 100 days. The composition can be synthesized by bringing together a radioisotope having a half life of less than 100 days with a greater than stoichiometric amount of a complexing agent so as to form a first mixture containing a reaction product between the radioisotope and the complexing agent; removing the excess complexing agent from the mixture; and bringing together the first reaction product and an antibody substance so as to form a second mixture containing a reaction product between the first reaction product and the antibody substance. The composition is useful for treating infectious diseases caused by pathogens.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: March 16, 2004
    Assignee: RX/IBR Corporation
    Inventors: Arthur Dale Ericsson, Daniel Hrna, Thomas J. Maloney
  • Patent number: 6270756
    Abstract: The invention is based on the discovery that substances which release ZAG proteins from lymphocytes also cause accelerated weight loss in humans. By administering an amount of the substance which is effective to cause the weight loss but is beneath an amount which causes side effects, a very desirable “dieter's aid” is provided. A dilute mixture of alfa interferon and gamma interferon in an aqueous medium is highly suitable for this purpose. It is administered at a much lower dosage than is generally employed for antibiotic purposes, thereby avoiding generally universal side effects. For periods of time extending at least for a few days, the weight loss composition of the invention causes weight loss at a greater weight than would be expected from fasting, at least for seriously overweight individuals.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: August 7, 2001
    Assignee: RX/IBR Corporation
    Inventor: Arthur Dale Ericsson